What has the MHRA said?

The Medicines and Healthcare products Regulatory Agency (MHRA) has reiterated that all GLP-1 receptor agonists — including semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro) and liraglutide (Saxenda) — are prescription-only medicines (POMs) in the UK. The regulator has flagged concerns about improper supply, particularly through online channels and aesthetic clinics that may be dispensing these products without valid prescriptions or appropriate medical oversight.

Why is this significant now?

The MHRA's intervention comes amid surging demand for GLP-1 weight-loss medicines. Several factors have intensified regulatory scrutiny:

  • Online supply chains: A proliferation of websites and social media sellers offering GLP-1 products without requiring a prescription has raised patient-safety concerns.
  • Unlicensed variants: Some suppliers have marketed research-grade GLP-1 peptides (including semaglutide sodium and tirzepatide salts) for human use, which the MHRA considers unlicensed medicines subject to enforcement action.
  • Adverse event reports: The MHRA Yellow Card scheme has received reports of adverse reactions linked to improperly sourced GLP-1 products, including incorrect dosing and counterfeit substances.

UK legal framework

Under the Human Medicines Regulations 2012:

  • GLP-1 receptor agonists are classified as POMs — they may only be supplied against a valid prescription issued by an appropriately qualified prescriber.
  • Supplying POMs without a prescription is a criminal offence punishable by up to two years' imprisonment.
  • Products must hold a marketing authorisation (licence) or be supplied under a specific exemption (such as a 'specials' licence for individual patients).

For research purposes, GLP-1 peptides may be sold by suppliers provided they are clearly labelled and marketed as 'not for human consumption' and 'for research use only'. However, the MHRA has indicated it will take enforcement action against suppliers that blur the line between research-grade and medicinal products.

What does this mean for peptide researchers?

The MHRA's position has several practical implications:

  1. Research-grade supply remains legal: Suppliers selling GLP-1 peptides for bona fide research purposes — with appropriate labelling and no implied medicinal use — are not the primary target of enforcement. However, the regulatory climate demands meticulous compliance.

  2. Blurred lines are a risk: Vendors that market research peptides with dosing instructions, protocol guidance, or language implying human use may attract MHRA attention. The SOP for UK peptide vendors requires clear 'research use only' labelling.

  3. Quality assurance matters: With the MHRA flagging counterfeit and incorrectly dosed products, researchers should prioritise vendors that provide third-party certificates of analysis (CoAs) and can demonstrate supply-chain integrity.

  4. NICE guidance context: The recent NICE recommendation of tirzepatide (Mounjaro) for obesity on the NHS (TA1026) has increased legitimate demand, which may further strain the research-supply market as demand for APIs rises.

Related reading

How to stay compliant

UK-based peptide researchers should ensure that:

  • All purchases are from suppliers with clear 'research use only' labelling
  • Products are accompanied by certificates of analysis from accredited third-party laboratories
  • No products are represented or used as medicines
  • Storage and handling follow research-grade protocols

This article is for research and educational purposes only and does not constitute medical or legal advice. Researchers with specific compliance questions should consult a qualified regulatory professional.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.